List of Excipients in Branded Drug THYROSHIELD

Generic Drugs Containing THYROSHIELD

Company	Ingredient	NDC	Excipient
Fleming & Company Pharmaceuticals	potassium iodide	0256-0210	FD&C BLUE NO. 1
Fleming & Company Pharmaceuticals	potassium iodide	0256-0210	FD&C RED NO. 40
Fleming & Company Pharmaceuticals	potassium iodide	0256-0210	METHYLPARABEN
Fleming & Company Pharmaceuticals	potassium iodide	0256-0210	PROPYLENE GLYCOL
Fleming & Company Pharmaceuticals	potassium iodide	0256-0210	PROPYLPARABEN
Fleming & Company Pharmaceuticals	potassium iodide	0256-0210	SACCHARIN SODIUM

What are the Most Frequently-Used Excipients in THYROSHIELD?

# Of NDCs	Excipient
2	FD&C BLUE NO. 1
2	FD&C RED NO. 40
2	METHYLPARABEN
2	PROPYLENE GLYCOL
2	PROPYLPARABEN
2	SACCHARIN SODIUM

ThyroShield Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

ThyroShield is a potassium iodide oral solution used for thyroid blocking after exposure to radioactive iodine. Its commercial value is driven by emergency preparedness, public-sector procurement, hospital stockpiling and packaging convenience rather than conventional chronic-drug demand. The formulation is relatively simple and has limited composition-based patent potential. The strongest opportunities are in dosing accuracy, palatability, stability, unit-dose packaging, procurement logistics and regulatory positioning.

What is ThyroShield and how is it regulated?

ThyroShield is marketed as potassium iodide oral solution, USP, at 65 mg/mL. Each milliliter contains 65 mg of potassium iodide, equivalent to approximately 50 mg of iodide. The product is used to reduce thyroid uptake of radioactive iodine during a radiological or nuclear emergency.

Attribute	ThyroShield profile
Brand	ThyroShield
Active ingredient	Potassium iodide
Dosage form	Oral solution
Strength	65 mg/mL potassium iodide
Approximate iodide content	50 mg/mL
Primary use	Thyroid blocking after radioactive iodine exposure
Administration	Oral, with age-based dosing
Prescription status	Emergency-use pharmaceutical product; regulatory status depends on the specific marketed presentation and FDA listing
Biosimilar relevance	None
Primary customers	Government agencies, hospitals, emergency-response organizations, nuclear facilities and households

FDA guidance states that potassium iodide should be used only when public-health authorities recommend it. It does not protect against other radioactive materials or external radiation exposure (FDA, 2018).

The product is a small-volume, high-concentration liquid. That creates technical requirements that are more important than the number of excipients: chemical stability, dose measurement, container compatibility, taste masking and resistance to microbial contamination.

What excipients are used in ThyroShield?

Public product labeling identifies an aqueous excipient system that includes purified water and buffering or stabilizing components. Depending on the marketed presentation and current label version, the formulation may include sodium thiosulfate, citric acid, sodium citrate and flavoring or other palatability agents. The FDA-approved or current commercial label controls the legally relevant composition.

A representative excipient strategy is:

Excipient function	Candidate or reported component	Commercial purpose
Vehicle	Purified water	Dissolves potassium iodide and supports oral administration
Buffering	Citric acid and sodium citrate	Controls pH and supports chemical stability
Stabilization	Sodium thiosulfate	May reduce iodine-related oxidative or discoloration pathways
Palatability	Flavoring agent	Improves acceptance, particularly in pediatric use
Sweetening or mouthfeel	Product-dependent	Reduces saltiness and bitterness
Packaging protection	Container and closure system	Limits evaporation, contamination and dose loss

Potassium iodide is highly water-soluble, which allows a concentrated oral solution without complex solubilization technology. The formulation therefore does not require a lipid system, surfactant platform, amorphous solid dispersion or modified-release excipient.

Which excipients are most important for product performance?

The most consequential formulation variables are pH, iodine-related impurities, container compatibility and dose uniformity.

A low-risk excipient platform should:

1. Maintain a controlled pH without excessive acidity.
2. Minimize oxidation of iodide and formation of free iodine.
3. Prevent visible discoloration during shelf life.
4. Avoid excipients that create pediatric toxicity or tolerability concerns.
5. Preserve accurate dosing after repeated opening.
6. Remain stable across emergency-storage conditions.

Sodium thiosulfate has a potential role as a reducing or stabilizing agent, but its inclusion must be justified through compatibility, assay, impurity and stability data. The formulation should not rely on an excipient merely because it appears in a legacy product. Each component should have a defined quality and regulatory function.

What formulation patents protect ThyroShield?

No widely recognized composition-of-matter patent estate appears to protect potassium iodide itself or the basic 65 mg/mL oral-solution concept. Potassium iodide is an established active ingredient, and the core formulation is technically straightforward.

IP category	Likely protection level	Commercial assessment
Potassium iodide active ingredient	None for modern commercial entry	Public-domain, established compound
Basic aqueous oral solution	Low	Broad claims would face prior-art challenges
Buffer and stabilizer combination	Low to moderate	Possible only with unexpected stability or shelf-life data
Flavor system	Low	Protectable mainly through formulation secrecy or narrow claims
Unit-dose packaging	Moderate	Potentially stronger if linked to dose accuracy and emergency use
Dispensing device	Moderate	Opportunity exists for child-appropriate and field-use systems
Manufacturing process	Moderate	Protection depends on impurity control, filling and stability results
Labeling or method of use	Limited	Public-health instructions constrain differentiation
Trade dress and branding	Commercially relevant	Trademark and procurement recognition can matter more than patents

The most defensible patent strategy would focus on a defined technical result. Examples include extended stability under elevated temperatures, reduced iodide oxidation, a specific low-volume delivery system, improved dose accuracy or a package designed for emergency distribution.

A generic claim covering "potassium iodide in water with a buffer" would likely have limited strength unless supported by unexpected results and carefully selected concentration, pH, excipient ratios and packaging conditions.

What is the Orange Book status of ThyroShield?

ThyroShield does not have the typical patent profile of a protected small-molecule innovator product. Publicly available FDA Orange Book materials do not identify a prominent, commercially significant patent estate associated with the basic potassium iodide oral-solution formulation.

The likely market implications are:

• No meaningful composition patent barrier for potassium iodide.
• Limited value in Paragraph IV litigation unless a specific listed patent exists for the product or delivery system.
• Potential entry through an ANDA or other applicable FDA pathway, depending on the reference product and current regulatory classification.
• Greater importance for bioequivalence, pharmaceutical equivalence, labeling, stability, container closure and manufacturing compliance than for patent litigation.

A competitor should verify the current Orange Book listing, FDA product database and active labeling before launching. Patent status can change through product-specific listings, although an established potassium iodide solution generally presents a low patent barrier.

When does ThyroShield lose exclusivity?

ThyroShield has no apparent conventional small-molecule exclusivity period comparable to a new chemical entity. The active ingredient is longstanding, and any product-specific exclusivity would depend on the approved application, labeling, pediatric studies or other FDA-recognized regulatory events.

The practical exclusivity analysis is:

Exclusivity type	Relevance to ThyroShield
New chemical entity exclusivity	Not applicable to potassium iodide
New clinical investigation exclusivity	Possible only if supported by qualifying FDA-recognized studies
Orphan-drug exclusivity	Not expected for this emergency-use product
Pediatric exclusivity	Not established from the basic product profile
Patent term	No central composition patent identified
Trademark exclusivity	Relevant to brand recognition and procurement
Contractual procurement exclusivity	Possible in government or institutional contracts

A competitor may face commercial barriers even without patent exclusivity. These include supplier qualification, government purchasing cycles, emergency-use contracts, inventory requirements, pharmacovigilance systems and the need to maintain available stock before an event occurs.

What excipient strategy offers the strongest commercial opportunity?

The best strategy is a low-complexity formulation with measurable performance advantages.

1. Improve pediatric palatability

Children are a core use population in radiological emergencies. Potassium salts can produce a salty, bitter or metallic taste. A product with better flavor acceptance could compete without changing the active ingredient.

Commercial approaches include:

• A controlled sweetener-flavor system.
• A reduced-volume, higher-concentration presentation, where dosing remains acceptable.
• A flavor variant designed for pediatric use.
• A co-packaged oral syringe with clear volume markings.
• A formulation that does not require dilution before administration.

Taste claims should be supported by human acceptability data. A flavor change alone may not create strong patent protection, but it can improve procurement and household acceptance.

2. Develop unit-dose packaging

Emergency products are often distributed to households, schools, hospitals and first responders. Unit-dose packaging can reduce measurement errors and improve inventory control.

Potential formats include:

• Premeasured oral syringes.
• Single-use ampoules.
• Blow-fill-seal units.
• Tamper-evident bottles with calibrated dosing devices.
• Multi-dose bottles with an integrated syringe adapter.

The commercial advantage is operational. A package that reduces dosing confusion and remains usable without a separate measuring device may be more valuable than a new excipient.

3. Strengthen temperature stability

Government and institutional stockpiles may be stored for long periods and exposed to temperature excursions. A formulation with validated stability under accelerated and excursion conditions could support longer dating or lower replacement costs.

Relevant development work includes:

• pH optimization.
• Control of iodine and iodate impurities.
• Light-protection studies.
• Extractables and leachables testing.
• Container-closure integrity.
• Stability after opening.
• Freeze-thaw and high-temperature excursion testing.

A patentable formulation would need more than routine optimization. The strongest claim would link a specified excipient ratio and container system to a demonstrated stability result.

How strong is the patent estate for ThyroShield?

The patent estate appears weak for the core drug product and potentially moderate for differentiated delivery systems.

A practical strength assessment is:

Area	Patent strength	Why
Active ingredient	Very low	Long-established compound
Concentration alone	Low	Likely exposed to prior art
Basic liquid formulation	Low	Conventional aqueous technology
Stabilized formulation	Low to moderate	Strength depends on unexpected results
Pediatric flavoring	Low	Easy design-around risk
Unit-dose delivery	Moderate	Device and packaging claims may be available
Shelf-life enhancement	Moderate	Stronger if data show a non-obvious result
Manufacturing controls	Moderate	Process claims may protect impurity reduction
Brand and procurement position	Moderate to high commercially	Difficult to replicate quickly despite weak patents

The principal competitive moat is likely regulatory execution and supply reliability, not patent exclusivity.

Which companies are challenging ThyroShield?

The main competitive threat is likely to come from other potassium iodide products rather than a branded challenger targeting ThyroShield specifically. Relevant competitive formats include:

• ThyroSafe potassium iodide tablets.
• Generic potassium iodide tablets.
• Generic potassium iodide oral solutions.
• Compounded hospital or pharmacy preparations.
• Government-procured potassium iodide stockpiles.
• Imported or jurisdiction-specific iodine-blocking products.

Tablets may have advantages in stability, portability and unit dosing. Oral solutions have advantages for young children and patients unable to swallow tablets. A liquid competitor can differentiate through dose accuracy, flavor, shelf life and packaging.

What generic entry risks exist?

Generic entry risk is high at the formulation level and moderate at the commercial level.

Regulatory risks

A competing product must address:

• Pharmaceutical equivalence.
• Strength and concentration.
• Assay and impurity specifications.
• pH and appearance.
• Microbial quality.
• Container-closure performance.
• Stability and expiration dating.
• Dose-delivery accuracy.
• Labeling consistency.
• Manufacturing-site compliance.

Because potassium iodide is highly soluble, formulation complexity does not create a major technical barrier. A competitor could potentially enter with a conventional aqueous solution if it satisfies FDA requirements.

Commercial risks

The market is episodic. Demand may remain low during ordinary periods and increase sharply after a radiological incident, government warning or emergency procurement event. That creates inventory and forecasting risks:

• Stock may expire before use.
• Government demand may be concentrated in periodic solicitations.
• Retail demand may be limited outside emergency periods.
• Price competition can be severe in tenders.
• Supply disruptions can quickly alter market share.
• Public agencies may favor suppliers with established emergency-distribution infrastructure.

What licensing deals could support ThyroShield growth?

A licensing strategy would be more valuable for distribution and packaging than for the active ingredient.

Potential counterparties include:

• Government emergency-stockpile contractors.
• Hospital group purchasing organizations.
• Nuclear power operators.
• Emergency medical suppliers.
• Pediatric pharmaceutical distributors.
• International public-health agencies.
• Packaging companies with unit-dose technology.

The most commercially relevant deal structures would include minimum-volume commitments, government tender support, regional distribution rights, private-label supply, co-development of delivery devices and long-term inventory agreements.

Licensing a generic excipient platform alone would probably have limited value. A package that combines formulation, validated stability, dosing hardware and regulatory documentation would offer a stronger transaction basis.

What is the FDA regulatory opportunity?

The primary regulatory opportunity is a differentiated product that remains within the established potassium iodide use case while improving administration.

Potential FDA-facing claims include:

• Improved dose accuracy.
• Pediatric administration.
• Reduced preparation steps.
• Longer shelf life.
• Better stability after opening.
• Improved container-closure protection.
• Reduced risk of accidental dosing errors.

A sponsor should avoid unsupported claims that the product protects against radiation generally. FDA guidance limits potassium iodide use to blocking radioactive iodine uptake by the thyroid (FDA, 2018).

A reformulated product may require a product-specific regulatory strategy based on the reference product, application status and degree of formulation change. The product’s emergency-use positioning does not eliminate requirements for chemistry, manufacturing and controls data.

What revenue exposure does ThyroShield have?

Revenue is exposed to procurement timing rather than prescription volume. Key revenue channels are:

Channel	Demand pattern	Commercial value
Federal or state stockpiles	Large, episodic purchases	High volume, tender-driven
Hospitals	Recurring inventory replacement	Moderate
Nuclear facilities	Contracted preparedness supply	Moderate
Schools and municipalities	Periodic preparedness purchases	Moderate
Retail pharmacies	Low baseline, event-driven spikes	Variable
International agencies	Tender-based	Potentially high
Direct-to-consumer	Limited routine demand	Lower margin and lower predictability

A product with lower total cost of ownership can compete effectively even if its unit price is higher. Relevant factors include expiration period, replacement frequency, storage requirements, packaging waste, dosing-device inclusion and shipping efficiency.

Key Takeaways

• ThyroShield is a potassium iodide oral solution, generally marketed at 65 mg/mL.
• The basic active ingredient and aqueous formulation have low patent barriers.
• No prominent Orange Book patent estate is associated with the core potassium iodide solution concept.
• The most attractive formulation opportunities are taste masking, dose accuracy, temperature stability and container compatibility.
• Unit-dose packaging and integrated oral syringes may create stronger commercial differentiation than new excipients.
• Generic entry risk is high because potassium iodide is established and highly water-soluble.
• Government procurement, emergency stockpiles, hospitals and nuclear facilities are the primary commercial markets.
• Licensing value is concentrated in distribution, packaging technology, private-label supply and procurement access.
• No biosimilar issue exists because ThyroShield is a small-molecule drug, not a biologic.
• The strongest defensible IP would likely cover a validated formulation-package system with measurable stability or dosing advantages.

FAQs

Is ThyroShield the same as ThyroSafe?

Both products contain potassium iodide for thyroid blocking, but ThyroShield is associated with an oral-solution presentation while ThyroSafe is commonly associated with tablets. The products differ in dosing flexibility, storage, packaging and pediatric administration.

Can potassium iodide oral solution be compounded by pharmacies?

Compounding may be possible under applicable federal and state rules, but a compounded preparation is not automatically equivalent to a commercially manufactured, stability-supported product. Shelf life, microbial control, concentration accuracy and labeling are critical.

Does a better flavor create patent protection for a potassium iodide product?

Flavoring alone usually creates weak patent protection because competitors may substitute other flavors. Stronger protection would require a defined formulation and evidence of an unexpected improvement in stability, acceptability or dose completion.

Is ThyroShield protected by orphan-drug exclusivity?

The basic potassium iodide oral-solution profile does not indicate orphan-drug exclusivity. Orphan status would require a product-specific FDA designation and approval history.

What is the best commercial format for pediatric emergency use?

A stable, premeasured liquid dose with an oral syringe, tamper-evident packaging and acceptable taste is likely to offer the strongest pediatric usability profile. Its commercial advantage would depend on validated stability, dosing accuracy and procurement economics.

References

1. U.S. Food and Drug Administration. (2018). Potassium iodide as a thyroid blocking agent in a radiation emergency. https://www.fda.gov/radiation-emitting-products/radiation-emergency-preparedness-and-response/potassium-iodide-ki

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. National Library of Medicine. (n.d.). DailyMed: ThyroShield potassium iodide oral solution labeling. https://dailymed.nlm.nih.gov

4. U.S. Food and Drug Administration. (2019). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.